Navigation Links
Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium
Date:9/9/2011

.nektar.com/">http://www.nektar.com.

Forward-Looking StatementsThis press release contains forward-looking statements that reflect management's current views regarding NKTR-102 and certain other drug candidates in Nektar's pipeline.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, regulatory delay, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; (iv) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (v) the outcome of any future intellectual property or other litigation related to Nektar's proprietary product candidates or complex commercial agreements; and (vi) certain other important risks and uncertainties set forth in Nektar's reports and other filings with the Sec
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
(Date:12/22/2014)... YORK , Dec. 22, 2014  Relmada ... novel therapies for the treatment of chronic pain, ... has been dosed in a pharmacokinetic and pharmacodynamic ... antagonist for neuropathic pain. Racemic methadone ... of various pain states and substitution therapy in ...
(Date:12/19/2014)...  Newport Corporation (NASDAQ: NEWP ) ... the company,s Board of Directors.  Dr. Kadia is ... of Evans Analytical Group, a leading global provider ... to companies in a wide range of industries.   ... Group, Dr. Kadia spent nine years with Life ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... Reportlinker.com announces that a new market research report ... The U.S. Medical Laboratories Industry - 10th Edition ... best-selling Marketdata study is a comprehensive analysis of the ... business. The industry was hurt by the recession but ...
... (Nasdaq: OREX ) announced today the upcoming resignation ... Mr. Cooper, who has been with Orexigen for over four ...  He has been commuting from the San Francisco Bay Area ... remain in his current role at Orexigen until the reporting ...
Cached Medicine Technology:Reportlinker Adds The U.S. Medical Laboratories Industry - 10th Edition 2Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer 2Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer 3
(Date:12/22/2014)... Shanghai, China (PRWEB) December 22, 2014 ... for MabThera (rituximab) for the treatment of non-Hodgkin’s lymphoma ... Health , a leading global healthcare consulting firm. MabThera ... B-cell lymphoma (DLBCL), the most common form of NHL. ... Market Access and Barriers,” the incidence of NHL in ...
(Date:12/22/2014)... Give a loved one the greatest ... health and vitality. , For a limited time, HealthiPlus ... formulas in special Holiday Wellness gift packages at drastically ... Each bottle contains cutting-edge, proven nutritional support for joints, ... well as we age. , Joint Health ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... December 22, 2014 NAPW ... Professional Woman of the Year. She is recognized with ... largest, most recognized networking organization of professional women in ... National Association of Professional Women is a vibrant networking ... Chapters. , Ms. Kreider is passionate and committed to ...
(Date:12/21/2014)... 2014 In this report, the ... power source, product, and application. The market, by ... pneumatic instruments. By product, the market covers the ... The handpieces market is further subdivided into drills, ... laparoscopic instruments, shavers, wire/pin drivers, and others. Moreover, ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... Australian-based,natural health care products company that markets a range ... nature identical ingredients,announced today that its Quit Nits head ... United States through a distribution agreement with,CVS Pharmacies., ... agreement was the,result of two years of hard work ...
... identified a gene that is the key switch that ... , Much like students in a kindergarten class lining ... is identified as Smarcd3, must align correctly with two ... known as myogenesis, said principal investigator Monte Westerfield, a ...
... is a company with a renowned track record ... high throughput technologies. Genomatix algorithms include optimized fast ... complete genome annotation in terms of transcriptome and ... databases in this specific content by a factor ...
... of us probably don,t think much,about being regular, ... Johanson,practicing gastroenterologist at the Beloit Clinic in Beloit, ... health is that we,re,not getting enough fiber., ... http://media.medialink.com/WebNR.aspx?story=34435 Registered journalists can access video, ...
... the top killers in the country, but youd never know it ... of the Society for Critical Care Medicine (SCCM). , Research ... blood pressure, yet many of them dont even know it. ... the medications they need to control it," says Dr. Christopher Granger, ...
... improves access by ... care facilities and consumers, BUFFALO, N.Y., Jan. ... health care provider network to provide,routine wellness and ... the company announced today., HealthTransaction Network connects ...
Cached Medicine News:Health News:Wild Child's 'Quit Nits' Offers a Safe, Natural Alternative to Current Toxic Head Lice Products 2Health News:Wild Child's 'Quit Nits' Offers a Safe, Natural Alternative to Current Toxic Head Lice Products 3Health News:Oregon researchers find trigger gene for muscle development 2Health News:Severe hypertension: 'Silent killer' still on the loose 2Health News:Buffalo Company Launches First-ever National Electronic Transaction Network to Improve Health Care Access for Uninsured and Underinsured 2Health News:Buffalo Company Launches First-ever National Electronic Transaction Network to Improve Health Care Access for Uninsured and Underinsured 3
... The AFX Lens is ... for use in an air-filled ... use as a primary air-fluid ... profile and sutureless design make ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
Medicine Products: